BioAssay Works, LLC (BAW) powers the development of the finest rapid immunoassays. Utilizing our high sensitivity concentrated gold sols, high-performance gold conjugates, and our patented lateral-flow test platform, BAW develops and manufactures rugged lateral-flow tests that rival the sensitivity of ELISA. These tests can be read visually for quick positive/negative results or with simple instruments for more quantitative results.
BioAssay Works is evolving to meet the needs of customers and a changing market to become a leading assay development partner-of-choice for both early-stage and established companies.
BioAssay Works operates a Quality Management System which is certified to ISO 13485:2016. This certification covers the development and manufacture of lateral flow assays, components, and reagents used in IVD medical devices. For a copy of BioAssay Works’ certificate, please click here.
BioAssay Works Quality Policy
BioAssay Works is committed to meeting applicable requirements, maintaining the effectiveness of the Quality Management System (QMS), and increasing customer satisfaction through continual improvement of its products, services and the QMS.
Vice President
Marketing & Business Development
Les joined BAW in 2016 with over 30 years of marketing and sales experience. In previous roles, he was responsible for product management, marketing, and sales of veterinary diagnostic and life science research product lines. Les leads the worldwide sales, marketing and business development efforts at BioAssay Works. He also manages many of the project teams developing custom lateral flow assays for BAW clients.
Executive Vice President
Research & Development
Dr. Olivier Côté obtained his PhD in Pathobiology (Molecular biology) from the University of Guelph, Canada in 2014. He has over 10 years of experience in the development of lateral flow assays (LFAs). At BAW, he has worked on over 80 client development projects and successfully helped them rapidly enter the market. He is an expert at trouble-shooting LFAs by root cause analyses and protocol optimization. Olivier leads the R&D team in design development and control of LFAs under ISO 13485.
Vice President
Operations
Marc joined BAW in 2019 with over 30 years of Operations experience. In his previous roles, he has provided leadership in both day to day tactical actions as well as creating the long-term strategic vision in Lean Manufacturing, Production Planning, Supply Chain Management and Facility Engineering for medical device, research reagent and industrial component manufacturers under various regulatory and quality standards such as ISO 13485, ISO 9001, cGMP, USDA, UL, ATEX/IEX and others. Marc leads the Operations and Quality teams at BAW.